Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Plunged Today

By Joe Tenebruso - Updated May 19, 2020 at 4:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech leader is selling stock, leading some investors to take their profits off the table.

What happened 

Shares of Moderna (MRNA -0.37%) fell 10% on Tuesday after the biotechnology company said it would seek to raise more than $1.3 billion in cash via a public share offering. 

So what 

Moderna's stock sale comes soon after it announced positive results from its phase 1 study for its coronavirus vaccine candidate mRNA-1273. Moderna's shares popped 20% on Monday following the news.

Now, it appears that the biotech company is using its stock's gains to sell shares at a higher price. Moderna priced its stock offering at $76 per share, which is about 14% higher than where it closed on Friday. 

But the offering price is lower than the price at which Moderna's shares closed on Monday, and its stock price fell in kind.

A stock chart that rises then falls

Shares of Moderna fell on Tuesday after rising sharply on Monday. Image source: Getty Images.

Now what

Moderna intends to use the proceeds from the stock sale to fund the manufacturing of mRNA-1273 for distribution in the U.S. and international markets, pending regulatory approval. The company also said that any funds not needed for the production of mRNA-1273 will be used for the research and development of other drugs in its pipeline, as well as technology investments and general corporate purposes. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.18 (-0.37%) $0.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.